A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29, p.viii334-viii335 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | viii335 |
|---|---|
| container_issue | |
| container_start_page | viii334 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Liu, J.F. Herold, C. Luo, W. Penson, R. Horowitz, N. Konstantinopoulos, P. Castro, C. Curtis, J. Matulonis, U.A. Cannistra, S. Dizon, D.S. |
| description | |
| doi_str_mv | 10.1093/annonc/mdy285.146 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy285_146</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419493988</els_id><sourcerecordid>32136788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2786-8b97271ef6cd3e7c5dcec0c97954f95ab37a8ff147425d755d5a05e5b22c6e4b3</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotlYfwI3kBabNZTKZ4KoUL4WCG7sOuZzBSCcpmXagPr2joy5dHQ783885H0K3lMwpUXxhYkzRLVp_YrWY07I6Q1MqKlXUpKTnaEoU44UUvJygq657J4RUiqlLNOGM8krW9RRtl3j_ZjrA6zU-5GB2ODXYpdaGaA4hRRxDn3bH1lhsoscWeuPCx_ceIs7gjjlDPODUm4GO2JnoIF-ji8bsOrj5mTO0fXx4XT0Xm5en9Wq5KRyTdVXUVkkmKTSV8xykE96BI05JJcpGCWO5NHXT0FKWTHgphBeGCBCWMVdBafkM0bHX5dR1GRq9z6E1-aQp0V-K9KhIj4r0oGhg7kZmf7Qt-D_i18kQuB8DMFzeB8i6cwGGt3wY_j1on8I_9Z9PXXp9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Liu, J.F. ; Herold, C. ; Luo, W. ; Penson, R. ; Horowitz, N. ; Konstantinopoulos, P. ; Castro, C. ; Curtis, J. ; Matulonis, U.A. ; Cannistra, S. ; Dizon, D.S.</creator><creatorcontrib>Liu, J.F. ; Herold, C. ; Luo, W. ; Penson, R. ; Horowitz, N. ; Konstantinopoulos, P. ; Castro, C. ; Curtis, J. ; Matulonis, U.A. ; Cannistra, S. ; Dizon, D.S.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy285.146</identifier><identifier>PMID: 32136788</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii334-viii335</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2786-8b97271ef6cd3e7c5dcec0c97954f95ab37a8ff147425d755d5a05e5b22c6e4b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32136788$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, J.F.</creatorcontrib><creatorcontrib>Herold, C.</creatorcontrib><creatorcontrib>Luo, W.</creatorcontrib><creatorcontrib>Penson, R.</creatorcontrib><creatorcontrib>Horowitz, N.</creatorcontrib><creatorcontrib>Konstantinopoulos, P.</creatorcontrib><creatorcontrib>Castro, C.</creatorcontrib><creatorcontrib>Curtis, J.</creatorcontrib><creatorcontrib>Matulonis, U.A.</creatorcontrib><creatorcontrib>Cannistra, S.</creatorcontrib><creatorcontrib>Dizon, D.S.</creatorcontrib><title>A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKAzEUhoMotlYfwI3kBabNZTKZ4KoUL4WCG7sOuZzBSCcpmXagPr2joy5dHQ783885H0K3lMwpUXxhYkzRLVp_YrWY07I6Q1MqKlXUpKTnaEoU44UUvJygq657J4RUiqlLNOGM8krW9RRtl3j_ZjrA6zU-5GB2ODXYpdaGaA4hRRxDn3bH1lhsoscWeuPCx_ceIs7gjjlDPODUm4GO2JnoIF-ji8bsOrj5mTO0fXx4XT0Xm5en9Wq5KRyTdVXUVkkmKTSV8xykE96BI05JJcpGCWO5NHXT0FKWTHgphBeGCBCWMVdBafkM0bHX5dR1GRq9z6E1-aQp0V-K9KhIj4r0oGhg7kZmf7Qt-D_i18kQuB8DMFzeB8i6cwGGt3wY_j1on8I_9Z9PXXp9</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Liu, J.F.</creator><creator>Herold, C.</creator><creator>Luo, W.</creator><creator>Penson, R.</creator><creator>Horowitz, N.</creator><creator>Konstantinopoulos, P.</creator><creator>Castro, C.</creator><creator>Curtis, J.</creator><creator>Matulonis, U.A.</creator><creator>Cannistra, S.</creator><creator>Dizon, D.S.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201810</creationdate><title>A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer</title><author>Liu, J.F. ; Herold, C. ; Luo, W. ; Penson, R. ; Horowitz, N. ; Konstantinopoulos, P. ; Castro, C. ; Curtis, J. ; Matulonis, U.A. ; Cannistra, S. ; Dizon, D.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2786-8b97271ef6cd3e7c5dcec0c97954f95ab37a8ff147425d755d5a05e5b22c6e4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, J.F.</creatorcontrib><creatorcontrib>Herold, C.</creatorcontrib><creatorcontrib>Luo, W.</creatorcontrib><creatorcontrib>Penson, R.</creatorcontrib><creatorcontrib>Horowitz, N.</creatorcontrib><creatorcontrib>Konstantinopoulos, P.</creatorcontrib><creatorcontrib>Castro, C.</creatorcontrib><creatorcontrib>Curtis, J.</creatorcontrib><creatorcontrib>Matulonis, U.A.</creatorcontrib><creatorcontrib>Cannistra, S.</creatorcontrib><creatorcontrib>Dizon, D.S.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, J.F.</au><au>Herold, C.</au><au>Luo, W.</au><au>Penson, R.</au><au>Horowitz, N.</au><au>Konstantinopoulos, P.</au><au>Castro, C.</au><au>Curtis, J.</au><au>Matulonis, U.A.</au><au>Cannistra, S.</au><au>Dizon, D.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii334</spage><epage>viii335</epage><pages>viii334-viii335</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32136788</pmid><doi>10.1093/annonc/mdy285.146</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29, p.viii334-viii335 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdy285_146 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A52%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20trial%20of%20combination%20nivolumab%20and%20bevacizumab%20in%20recurrent%20ovarian%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Liu,%20J.F.&rft.date=2018-10&rft.volume=29&rft.spage=viii334&rft.epage=viii335&rft.pages=viii334-viii335&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy285.146&rft_dat=%3Cpubmed_cross%3E32136788%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32136788&rft_els_id=S0923753419493988&rfr_iscdi=true |